Burke John M, Jurcic Joseph G
Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA.
Clin Lymphoma. 2002 Mar;2 Suppl 1:S12-8. doi: 10.3816/clm.2002.s.003.
Monoclonal antibodies have become an important modality for cancer therapy. The genetically engineered, humanized anti-CD33 antibody HuM195 has demonstrated modest activity against overt relapsed acute myeloid leukemia (AML) and more substantial activity against minimal residual disease in acute promyelocytic leukemia. Radioimmunotherpay with beta-particle-emitting isotopes has eliminated large leukemic burdens while minimizing radiation exposure to normal tissues in both nonmyeloablative and myeloablative regimens. Targeted beta-particle immunotherapy with agents such as bismuth 213-labeled HuM195 offers the possibility of a more selective tumor cell kill with less damage to surrounding normal cells. Directed chemotherapy using the anti-CD33-calicheamicin conjugate gemtuzumab ozogamicin (Mylotarg) has produced remissions in patients with relapsed AML.
单克隆抗体已成为癌症治疗的一种重要方式。基因工程改造的人源化抗CD33抗体HuM195已显示出对明显复发的急性髓系白血病（AML）有适度活性，对急性早幼粒细胞白血病的微小残留病有更强活性。使用发射β粒子的同位素进行放射免疫治疗，在非清髓性和清髓性方案中均消除了大量白血病负荷，同时将对正常组织的辐射暴露降至最低。用铋213标记的HuM195等药物进行靶向β粒子免疫治疗，有可能更有选择性地杀死肿瘤细胞，对周围正常细胞的损伤更小。使用抗CD33-卡奇霉素偶联物吉妥单抗（Mylotarg）进行定向化疗已使复发AML患者获得缓解。
